1. Home
  2. PLX vs TOYO Comparison

PLX vs TOYO Comparison

Compare PLX & TOYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLX
  • TOYO
  • Stock Information
  • Founded
  • PLX 1993
  • TOYO 2022
  • Country
  • PLX United States
  • TOYO Japan
  • Employees
  • PLX N/A
  • TOYO N/A
  • Industry
  • PLX Biotechnology: Biological Products (No Diagnostic Substances)
  • TOYO
  • Sector
  • PLX Health Care
  • TOYO
  • Exchange
  • PLX Nasdaq
  • TOYO NYSE
  • Market Cap
  • PLX 160.2M
  • TOYO 131.2M
  • IPO Year
  • PLX 1998
  • TOYO N/A
  • Fundamental
  • Price
  • PLX $2.87
  • TOYO $3.02
  • Analyst Decision
  • PLX Strong Buy
  • TOYO
  • Analyst Count
  • PLX 1
  • TOYO 0
  • Target Price
  • PLX $15.00
  • TOYO N/A
  • AVG Volume (30 Days)
  • PLX 753.1K
  • TOYO 10.1K
  • Earning Date
  • PLX 05-09-2025
  • TOYO 04-28-2025
  • Dividend Yield
  • PLX N/A
  • TOYO N/A
  • EPS Growth
  • PLX N/A
  • TOYO N/A
  • EPS
  • PLX 0.04
  • TOYO 0.76
  • Revenue
  • PLX $53,399,000.00
  • TOYO $200,455,385.00
  • Revenue This Year
  • PLX $65.02
  • TOYO N/A
  • Revenue Next Year
  • PLX $57.34
  • TOYO N/A
  • P/E Ratio
  • PLX $79.67
  • TOYO $3.94
  • Revenue Growth
  • PLX N/A
  • TOYO N/A
  • 52 Week Low
  • PLX $0.82
  • TOYO $1.36
  • 52 Week High
  • PLX $3.10
  • TOYO $15.61
  • Technical
  • Relative Strength Index (RSI)
  • PLX 56.85
  • TOYO N/A
  • Support Level
  • PLX $2.70
  • TOYO N/A
  • Resistance Level
  • PLX $2.64
  • TOYO N/A
  • Average True Range (ATR)
  • PLX 0.17
  • TOYO 0.00
  • MACD
  • PLX -0.01
  • TOYO 0.00
  • Stochastic Oscillator
  • PLX 61.67
  • TOYO 0.00

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

About TOYO TOYO CO LTD

Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.

Share on Social Networks: